Review article: the economic impact of the irritable bowel syndrome

Summary Background Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal system affecting a large number of people worldwide. Whilst it has no attributable mortality, it has substantial impact on patients' quality of life (QoL) and is associated with considerab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Alimentary pharmacology & therapeutics Ročník 40; číslo 9; s. 1023 - 1034
Hlavní autoři: Canavan, C., West, J., Card, T.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Oxford Blackwell 01.11.2014
Témata:
Absenteeism
Biological and medical sciences
Chronic Disease
Delivery of Health Care - economics
Gastroenterology. Liver. Pancreas. Abdomen
Health Care Costs
Health Expenditures
Health Resources - economics
Health Resources - statistics & numerical data
Humans
Internationality
Irritable Bowel Syndrome - economics
Irritable Bowel Syndrome - physiopathology
Irritable Bowel Syndrome - therapy
Life Expectancy - trends
Medical sciences
Other diseases. Semiology
Quality of Life
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Irritable bowel syndrome
Digestive diseases
Intestinal disease
Review
Economic aspect
Bibliographic review
Public health
ISSN:0269-2813, 1365-2036, 1365-2036
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Summary Background Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal system affecting a large number of people worldwide. Whilst it has no attributable mortality, it has substantial impact on patients' quality of life (QoL) and is associated with considerable healthcare resource use. Aim To review the economic impact of IBS, firstly on the individual, secondly on healthcare systems internationally and thirdly to society. Methods Appropriate databases were searched for relevant papers using the terms: Irritable Bowel Syndrome; IBS; irritable colon; functional bowel/colonic disease; economics; health care/service costs; health expenditure/resources; health care/service utilisation; productivity. Results Irritable bowel syndrome impacts most substantially on patients' work and social life. Reduction in QoL is such that on average patients would sacrifice between 10 and 15 years of their remaining life expectancy for an immediate cure. Between 15% and 43% of patients pay for remedies. No studies quantify loss of earnings related to IBS. Direct care costs are substantial; 48% of patients incur some costs in any year with annual international estimates per patient of: USA $742–$7547, UK £90–£316, France €567–€862, Canada $259, Germany €791, Norway NOK 2098 (€262) and Iran $92. Minimising extensive diagnostic investigations could generate savings and has been shown as not detrimental to patients. Cost to industry internationally through absenteeism and presenteeism related to IBS is estimated between £400 and £900 per patient annually. Conclusions Irritable bowel syndrome is associated with substantial costs to patients, healthcare systems and society. Considerable benefit could be obtained from effective interventions.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0269-2813
1365-2036
1365-2036
DOI:10.1111/apt.12938